TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Immutep Ltd ( (AU:IMM) ) just unveiled an announcement.
Immutep Ltd announced a change in the director’s interest, with Mr. Pete Meyers acquiring 2,058,631 Performance Rights as remuneration for his services. This acquisition, approved at the Annual General Meeting, reflects the company’s strategy to align director compensation with shareholder interests, potentially impacting its governance and stakeholder relations.
The most recent analyst rating on (AU:IMM) stock is a Hold with a A$0.28 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.
More about Immutep Ltd
Immutep Ltd is a biotechnology company focused on developing immunotherapy treatments. The company specializes in products that aim to harness the body’s immune system to fight cancer and autoimmune diseases, positioning itself as a leader in the immunotherapy market.
Average Trading Volume: 2,329,094
Technical Sentiment Signal: Sell
Current Market Cap: A$375.3M
For an in-depth examination of IMM stock, go to TipRanks’ Overview page.